Furthermore, fimepinostat is a dual HDAC and PI3K inhibitor reported to have an objective response rate (ORR) of 15% in patients with relapsed/refractory DLBCL or HGBL with high MYC (≥ 40%). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.